Fig. 2From: Bafilomycin A1 inhibits SARS-CoV-2 infection in a human lung xenograft mouse modelBaf-A1 improves the viability of Vero E6 cells after infection with SARS-CoV-2 variant strains. A Viability of Vero E6 cells treated with different doses of Baf-A1 after infection with SARS-CoV-2 (0.008 MOI) for 48 h. B Viability of Vero E6 cells treated with different doses of Baf-A1 and after infection with Beta variant (0.008 MOI) for 48 h. C Viability of Vero E6 cells treated with different doses of Baf-A1 and after infection with Delta variant (0.008 MOI) for 48 h. D Crystal violet staining assays of Vero E6 cells treated with Baf-A1 (0 and 500 nM) after infection (0.008 MOI) for 48 h. Three experiments were performed (n = 5 each group). *p < 0.05, **p < 0.01, ***p < 0.001Back to article page